MONMOUTH JUNCTION, N.J. and AIRPORT CITY, Israel, July 06, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight Ltd. (“Biosight”), a privately held pharmaceutical development ...

I am reaching out to you to share our excitement over Biosight’s proposed merger with Advaxis, Inc. (Nasdaq: ADXS) and explain why we believe the transaction represents a mutually compelling ...

"We are very pleased to have received from the FDA the Orphan Drug Designation for aspacytarabine for the treatment of MDS, which adds to the designation granted already for the treatment of AML" said ...

Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an investment of $13 million led by pharmaceutical investment firm Arkin Holdings, run ...

AIRPORT CITY, Israel, June 4, 2019 /PRNewswire/ -- Biosight Ltd., a pharmaceutical development company focused on the development of novel oncology therapeutics, announced today that the United States ...

AIRPORT CITY, Israel, Nov. 22, 2022 /PRNewswire/ -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced ...

AIRPORT CITY, Israel, July 11, 2018 /PRNewswire/ -- BioSight Ltd., a pharmaceutical development company focused on the development of targeted oncology drugs, announced today that it has received the ...

AIRPORT CITY, Israel, May 26, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today ...

AIRPORT CITY, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- ., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the ...

Biosight is a private clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight's lead product, aspacytarabine (BST-236), is an ...